Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   MEDICAL JOURNAL OF MASHHAD UNIVERSITY OF MEDICAL SCIENCES   SUMMER 2007 , Volume 50 , Number 96; Page(s) 171 To 176.
 
Paper: 

EFFICACY OF ORAL VERSUS INTRAVENOUS VITAMIN C ON SERUM OXALATE LEVEL IN HEMODIALYSIS PATIENTS

 
 
Author(s):  KASHI Z.*, ESPAHBODI F., ALA SH., HENDOUEI N.
 
* MEDICAL FACULTY, SARI, IRAN
 
Abstract: 

Introduction: Long term of high doses of vitamin C treatment might be a potential risk for the development of secondary oxalosis in end stage renal disease patients. Hyperoxalatemia may increase the risk of cardiac, vascular and bone diseases. Hemodialysis patients (HD) are at high risk for Scurvy disease due to dietary limitation and ascorbic acid losses through dialysis.

Vitamin C also decreases HTN and accelerated arthrosclerosis. Thus, vitamin C supplementation is necessary for these patients. The aim of this study was to evaluate efficacy of oral versus intravenous vitamin C on serum oxalate level in hemodialysis patients.

Material and Methods: This clinical-trial study was done on hemodialysis patients referred to the three treatment centers of Mazandaran Province. 41 HD patients, who had not consumed vitamin C for two months, were randomly divided into two groups, oral and intravenous. In intravenous (IV AA) group, vitamin C 500 mg/day was administered three times a week; and oral group received vitamin C 125 mg/day for two months. Oxalate serum level was measured before and after treatment. Individual, laboratory, and treatment complication data were gathered in a questionnaire.

Intra group comparison was done with t-student test and inter group comparison was done with independent- sample t-test. Data were expressed as SE±Mean and p-value<0.05 was considered significant.

Results: Serum oxalate level in each group increased, there was no significant differences intra group and between two groups (p=0.3) (in oral, from 1.8± 0.4mgl/L to 1.85±0.8 mgl/L, P=0.4 and in IVAA from 1.8±0.7 mg/L to 2.1±0.9 mg/L, P=0.3).
Conclusion: Oral and IV AA in the used dosage did not increase serum oxalate level and weresafe to use as supplementation in HD patients.

 
Keyword(s): ORAL AND IV VITAMIN C, HEMODIALYSIS PATIENTS, SERUM OXALATE LEVEL
 
References: 
  • ندارد
 
  Persian Abstract Yearly Visit 67
 
Latest on Blog
Enter SID Blog